Goal 3: Advance Translational Research

How can we develop more selective immunosuppression for allogeneic hematopoietic cell transplantation?

Graft versus host disease (GVHD) remains the most significant complication of allogeneic hematopoietic stem cell transplantation (HCT). While the use of HCT has grown significantly safer and has demonstrated broad efficacy in the setting of a broad range of blood diseases, immunosuppressive therapy has not dramatically evolved since the introduction of calcineurin inhibitor-based approaches decades ago. The availability of novel immunosuppressive agents that target donor immune responses responsible for GVHD without substantially impairing pathogen-specific immunity would allow us to treat a broader range of diseases, including nonmalignant disorders, and patients lacking well matched donors.

Tags (Keywords associated with the idea)


106 net votes
129 up votes
23 down votes
Idea No. 576